Astellas Pharma Europe Limited

Tweet this page
<
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 09 Apr 2024
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

300,000€ - 399,999€

Financial year: Apr 2023 - Mar 2024

Lobbyists (Full time equivalent)

1 Fte (2)

Lobbyists with EP accreditation

2

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    Astellas Pharma Europe Limited   (APEL)

    EU Transparency Register

    726065718920-12 First registered on 24 Sep 2015

    Goals / Remit

    At Astellas, we are relentless in our pursuit of scientific progress and in identifying unmet medical needs by monitoring the changes in healthcare from multiple perspectives. We are committed to the realization of greater value by patients and healthcare systems around the world. We achieve this by leveraging our strengths to create innovative new drugs and to find solutions that drive patient access to healthcare and better outcomes.

    Main EU files targeted

    Intellectual Property Rights and incentives - including Orphan Medicinal Products, Paediatric medicines
    Free Trade Agreements - EU/US, EU/UK,
    EU Beating Cancer Plan,
    EU Green Deal, Pharmaceuticals in the environment (PIE), the Circular Economy, Climate change, Energy taxes,
    Industrial strategy,
    Competition law,
    Horizon Europe,
    Innovative Health Initiative (IHI),
    European Medicines Agency (EMA),
    European Health Data Space (EHDS)
    Committee of the Regions,
    Clinical Trials Regulation,
    Data Protection Regulation,
    Digital health,
    Community code related to medicinal products for human use in mainly countries that are part of the European Union - General Pharma Legislation
    Other policy areas of interest include Manufacturing, Health outcomes, Real world evidence, Pricing, reimbursement and market access to medicines, cancer, healthcare sustainability, patient advocacy group payments, transfers of value to healthcare professionals and healthcare organisations.

    Address

    Head Office
    Bourne Business Park300 Dashwood Lang Road
    Addlestone KT15 2NX
    UNITED KINGDOM
    EU Office
    Bourne Business Park300 Dashwood Lang Road
    Addlestone KT15 2NX
    UNITED KINGDOM

    Website

    https://www.astellas.com/eu/

  • People

    Total lobbyists declared

    2

    Employment timeLobbyists
    75%1
    25%1

    Lobbyists (Full time equivalent)

    1

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    2 accreditations were / are live (in bold) for the selected state of 18 Apr 2024

    Name Start date End Date
    Rachel DIXON 20 Sep 2023 13 Sep 2024
    Melanie YAMMINE 20 Sep 2023 13 Sep 2024
    Ms Rachel Dixon 20 Sep 2023 15 Apr 2024
    Ms Melanie Yammine 20 Sep 2023 15 Apr 2024
    Ms Rachel Dixon 29 Mar 2022 29 Mar 2023
    Ms Melanie Yammine 29 Mar 2022 29 Mar 2023
    Ms Melanie Yammine 09 Nov 2018 09 Nov 2019

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    EFPIA
    Alliance for Regenerative Medicines

    Member organisations

    Alliance for Regenerative Medicines
    EFPIA

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Apr 2023 - Mar 2024

    Lobbying costs for closed financial year

    300,000€ - 399,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    to be completed 0€ - 10,000€

    Intermediaries for current year

    None declared

    Closed year Costs

    300,000€ - 399,999€

    Other financial info

    to be completed

  • EU Structures

    Groups (European Commission)

    None declared

    Groups (European Parliament)

    N/A

    Communication activities

    We are a member of the European Federation of Pharmaceutical Industries and Associations and its Oncology platform. We are also member of the Alliance for Regenerative Medicines.
    We are participating in events on industrial, health and life science policy.
    We are meeting with policy makers in the EU institutions and engaging with other public policy stakeholders.
    We are funding and participating in a campaign called Let's Talk Prostate Cancer and are engaged in roundtable on Combination Therapies and on Bladder Cancer.

    Other activities

    None declared

  • Meetings

    Meetings

    None declared

Download this datacard